ZTZeynep Cagla Tarcan

Zeynep Cagla Tarcan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zeynep Cagla Tarcan has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Target Antigen Identification for Antibody–Drug Conjugate Therapy in Biliary Tract Cancer

    by Aruj Dhyani, Nuray Tezcan, Joanne F. Chou, Zeynep Tarcan, Rohit Thummalapalli, Fatema Nagib, Orla M. Fitzpatrick, Darren Cowzer, Danny N. Khalil, Wungki Park, et al.

    Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected primary biliary tract cancer specimens and, when available, matched metastatic samples were assembled into tissue microarrays (TMA) and tested for CLAUDIN18.2 (CLDN18.2), c-MET, Nectin-4, TROP2, and HER2 expression by immunohistochemistry (IHC). A subset underwent targeted next-generation sequencing using MSK-IMPACT (NCT01775072). Exploratory associations of target expression with clinicopathologic parameters, genomic alterations, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: Sixty-five patients with resected biliary tract cancer and 18 paired metastatic sites were identified—43% extrahepatic cholangiocarcinoma, 40% intrahepatic cholangiocarcinoma, and 17% gallbladder cancer. All evaluated target antigens were expressed; percent positivity and H-score ≥200 were 83% and 26% for TROP2, 75% and 26% for c-MET, 66% and 35% for Nectin-4, and 46% and 7.7% for CLDN18.2, respectively. HER2 overexpression occurred in 3.1% of tumors. Overall agreement among paired primary and metastatic samples on calling either positive or negative ranged from 43% to 75%, with the highest observed for HER2 {75%; κ = 0.29 [95% confidence interval (CI), −0.32 to 0.91]} and TROP2 (71%; κ not available) and lowest for c-MET, CLDN18.2, and Nectin-4. Frequently altered genes included TP53 (36%), SMAD4 (27%), and ELF3 (21%). We observed no significant association between target antigen expression and genomics, RFS, or OS. Conclusions: Biliary tract cancer displays frequent but heterogeneous expression of multiple ADC targets. These hypothesis-generating findings suggest inherent complexity of target protein quantification, target threshold determination, and target sampling discordance. Future studies will be required to refine our understanding of the utility of ADCs in biliary tract cancer.

  • Open Access

    Supplementary Figures 1-6 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer

    by Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Stefan R. Torborg, Jung Yun Kim, Olivera Grbovic-Huezo, Huijin Feng, Zeynep Cagla Tarcan, Hulya Sahin Ozkan, et al.

    Supplementary Figure 1. KRAS inhibition promotes a classical differentiation state in mouse models of PDAC. Supplementary Figure 2. Gene expression analyses of KPF PDAC cells upon KRAS inhibition. Supplementary Figure 3. Generation and validation of a genetic reporter model to study classical cancer state dynamics in vivo. Supplementary Figure 4. In vivo dynamics of the classical state utilizing a distinct genetic reporter model. Supplementary Figure 5. Classical PDAC cells drive resistance to KRAS inhibition upon spontaneous tumor relapse. Supplementary Figure 6. KRAS inhibition promotes a classical cancer cell state in human PDAC.

  • Open Access

    Supplementary Table 1 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer

    by Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Stefan R. Torborg, Jung Yun Kim, Olivera Grbovic-Huezo, Huijin Feng, Zeynep Cagla Tarcan, Hulya Sahin Ozkan, et al.

    Supplementary Table 1 includes gene set enrichment analysis (GSEA) of KPF mouse PDAC cells comparing MRTX1133-treated vs. vehicle-treated classical and basal cells

  • Open Access

    Supplementary Methods from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer

    by Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Stefan R. Torborg, Jung Yun Kim, Olivera Grbovic-Huezo, Huijin Feng, Zeynep Cagla Tarcan, Hulya Sahin Ozkan, et al.

    Supplementary Methods includes additional detailed experimental methodology and description of computational analyses.

  • Open Access

    Supplementary Table 2 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer

    by Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Stefan R. Torborg, Jung Yun Kim, Olivera Grbovic-Huezo, Huijin Feng, Zeynep Cagla Tarcan, Hulya Sahin Ozkan, et al.

    Supplementary Table 2 includes primer sequences and antibodies used in this study.

  • Top Cited Papers

    Sensitive CAR T cells redefine targetable CD70 expression in solid tumors

    by Sophie A. Hanina, Tyler Park, Michael Lopez, Vinagolu K. Rajasekhar, Jorge Mansilla-Soto, Sascha Haubner, Huiyong Zhao, Friederike Kogel, Sarah Nataraj, Priyam Banerjee, et al.

    Solid tumor antigen heterogeneity is a major challenge for cancer immunotherapies, including chimeric antigen receptor (CAR) T cells. Unlike CD19 for B cell malignancies, no target with pan-cellular expression in solid tumors and absence in normal vital cells has been identified. CD70 is a promising candidate, physiologically confined to immune cell subsets and aberrantly expressed in many cancers. We show that heterogeneous CD70 expression in tumors is epigenetically regulated, ranging from high to very low in individual cells, appearing negative by conventional detection methods. Using a highly sensitive CD70 receptor, HLA-independent T cell (HIT) receptor coexpressing CD80 and 4-1BBL for costimulation, we efficiently eliminated CD70-heterogeneous tumors that evade prototypic CAR T cells. These findings provide a potential strategy to treat a broad range of solid tumors.


  • “Horses out of the barn”: pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification for accurate T‐staging

    by Burcu Saka, Bahar Memis, Serdar Balci, Ipek Erbarut Seven, Burcin Pehlivanoglu, Pelin Bagci, Rohat Esmer, Zeynep Tarcan, Jeanette D Cheng, Shishir K Maithel, et al.

    Aims: Accurate determination of tumour size is critical for pT staging in pancreatic ductal adenocarcinoma (PDAC), yet gross measurement alone often underestimates the true tumour extent because of the tumour's ill‐defined and infiltrative nature. This study aimed to evaluate the diagnostic and prognostic value of incorporating microscopic rectification into tumour size assessment in PDAC. Methods and results: A total of 342 therapy‐naïve pancreatoduodenectomies were analysed using a grossing protocol that includes separate sampling of anterior and posterior soft tissues via the ‘orange‐peeling’ technique to retrieve lymph nodes and document soft tissue involvement. Peripancreatic soft tissue involvement was present in 91% of cases, and isolated microscopic foci distant from the main mass in 48%. Of the 266 tumours grossly classified as pT1/T2 (≤4 cm), 39 (14%) showed carcinoma in both anterior and posterior soft tissues, and were reclassified as pT3. This subset showed significantly worse survival ( P = 0.04) and higher nodal positivity (87% versus 69%, P = 0.02) than the remaining pT2 cases, comparable to conventional pT3 tumours (86%, P = 0.77). Multivariable Cox regression adjusted for age, sex, nodal status, margin, and lymphovascular/perineural invasion confirmed the survival disadvantage of this subgroup. Reclassification yielded a more balanced distribution of T categories (pT2 66% → 52%, pT3 22% → 34%) and modestly improved prognostic discrimination (C‐index: 0.592 versus 0.574). Conclusions: This study elucidates that PDAC frequently extends beyond the visible mass (‘horses out of the barn’ phenomenon); peripancreatic soft tissue involvement is common, and gross size often underestimates the true tumour extent, making microscopic correction crucial. Approximately one in six pT1/T2 tumours (≤4 cm) shows carcinoma in both anterior and posterior soft tissues and behave like pT3 in outcomes and nodal status. Therefore, gross‐micro rectification is essential to avoid understaging, particularly for T2 tumours. The orange‐peeling protocol should classify tumours with foci in both anterior and posterior soft tissues as pT3, while other approaches may employ mapping techniques to enable microscopic reconstruction and biologically accurate staging.


  • Open Access

    NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer

    by Alison M Schram, Soo-Ryum Yang, Genessa Kahn, Rogelio Velasco, Matteo Repetto, Richard Kinh Gian Do, Sara DiNapoli, Purvil Sukhadia, Megan Troxel, Kerem Ozcan, et al.

    Background: NRG1 fusions are unique oncogenic drivers that activate the HER3/HER2/PI3K pathway. The US Food and Drug Administration granted accelerated approval to a HER2/HER3 antibody, zenocutuzumab, for treatment of NRG1 fusion-positive non–small cell lung cancer and pancreatic ductal adenocarcinoma (PDAC). The optimal detection methods and clinicopathological features of patients with NRG1 fusion-positive cancer have not been systematically studied. Here, we review NRG1 fusion-positive cancer and focus on outcomes in PDAC. Methods: Patients with NRG1 fusion-positive disease at Memorial Sloan Kettering Cancer Center were identified using institutional databases. Clinicopathological data were extracted from medical records. NRG1 fusion-positive PDAC cases underwent review of radiology, pathology, treatment data, and assessment of progression-free and overall survival. Results: Of 76 531 patients, 48 NRG1 fusion-positive cases were identified. The most common tumor types were lung (60%), PDAC (21%), and breast (10%). Approximately half (46%) of these patients received HER2- and/or HER3-directed therapy. Patients were identified by RNA (n = 34), DNA (n = 11), or both (n = 3). RNA was superior to DNA for fusion identification. Twenty-one fusion partners were detected, most commonly CD74 (40%) and ATP1B1 (10%). Lung cancers were otherwise driver negative, and PDAC cases were KRAS wild type. NRG1 fusion-positive PDAC exhibited distinct histopathological and clinical features. Median patient age was 48.5 years, median progression-free survival on first-line chemotherapy was 12.6 months (n = 7; 95% confidence interval [CI] = 2.9 to not reached), and median overall survival from diagnosis was 39.6 months (n = 9; 95% CI = 23.2 to not reached). Conclusions: NRG1 fusions are a newly described, clinically actionable target in solid tumors. We report the landscape of NRG1 fusion-positive cancers and highlight the importance of RNA testing. NRG1 fusion-positive PDAC is enriched in younger patients with KRAS wild-type disease and has unique biology.


  • Open Access

    Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms

    by Rohit Thummalapalli, Salomon Tendler, Joanne F. Chou, Zeynep C. Tarcan, Courtney Porfido, Jonathan Willner, Irina Linkov, Umesh Bhanot, Alissa J. Cooper, Jierui Xu, et al.

    PURPOSE: Delta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), including poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEP NECs) and well-differentiated neuroendocrine tumors (NETs). We aimed to define the landscape of DLL3 expression and feasibility of DLL3-targeted imaging in this population. PATIENTS AND METHODS: We completed DLL3 immunohistochemistry (IHC) on 379 tumor samples from patients with GEP NENs, analyzing associations between DLL3 IHC positivity, clinicopathologic features, and outcomes. [ 89 Zr]Zr-DFO-SC16.56 DLL3 immuno-positron emission tomography-computed tomography (immunoPET-CT) imaging was performed in six patients with DLL3 IHC-positive advanced GEP NENs. RESULTS: Among GEP NECs, DLL3 expression was identified in 55/78 (71%) tumors, was enriched for small cell histology, and did not demonstrate prognostic significance. Among well-differentiated gastroenteropancreatic neuroendocrine tumors, DLL3 expression was identified in 5/235 (2%) of grade 1-2 and 25/66 (40%) grade 3 (G3) tumors, most commonly G3 pancreatic NETs (PanNETs; 22/52, 43%), with univariate analysis revealing increased mortality risk among patients with DLL3-positive advanced G3 PanNETs (hazard ratio 3.27 [95% CI, 1.09 to 9.78]). Between May 28, 2024, and February 10, 2025, six patients with DLL3 IHC-positive GEP NENs underwent [ 89 Zr]Zr-DFO-SC16.56 immunoPET-CT imaging, which delineated DLL3-avid tumor lesions in five of six patients (two of two GEP NECs, three of four G3 PanNETs). Tumor-specific uptake of [ 89 Zr]Zr-DFO-SC16.56 varied between patients, with maximum standard uptake values ranging from 7.4 to 36.7, with four of six cases demonstrating DLL3 avidity in ≥50% of tumor lesions. CONCLUSION: DLL3 is expressed on a majority of GEP NECs and on a subset of high-grade PanNETs marked by poor outcomes. Functional imaging suggests DLL3 as a promising therapeutic target in both GEP NECs and high-grade PanNETs.


  • Open Access

    Supplementary Methods from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer

    by Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Stefan R. Torborg, Jung Yun Kim, Olivera Grbovic-Huezo, Huijin Feng, Zeynep Cagla Tarcan, Hulya Sahin Ozkan, et al.

    Supplementary Methods includes additional detailed experimental methodology and description of computational analyses.